Sphera Funds Management’s Climb Bio CLYM Stock Holding History

Sphera Funds Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.31M	Buy	483,747 +64,500	+15%	+$666K	0.82%	42
2026 Q1	$2.87M	Sell	419,247 -513,000	-55%	-$2.96M	0.46%	67
2025 Q4	$3.73M	Buy	932,247 +497,410	+114%	+$1.19M	0.72%	53
2025 Q3	$874K	Buy	434,837 +225,000	+107%	+$418K	0.18%	97
2025 Q2	$260K	Sell	209,837 -32,098	-13%	-$39.9K	0.06%	103
2025 Q1	$295K	Sell	241,935 -10,000	-4%	-$16.2K	0.07%	110
2024 Q4	$453K	Buy	251,935 +69,965	+38%	+$253K	0.08%	102
2024 Q3	$926K	Sell	181,970 -33,209	-15%	-$235K	0.15%	101
2024 Q2	$1.53M	Buy	+215,179	New	+$1.43M	0.21%	93

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sphera Funds Management's CLYM Position: Q2 2026 in Review

Sphera Funds Management increased its Climb Bio (CLYM) stake by 15% in Q2 2026, buying an estimated $666K and bringing the position to 483,747 shares worth $6.31M. The position accounts for 0.82% of the portfolio, ranked #42.

Sphera Funds Management first reported a position in CLYM in Q2 2024 and has held it in 9 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Sphera Funds Management held 483,747 shares of Climb Bio worth $6.31M as of Q2 2026.
Sphera Funds Management bought 64,500 Climb Bio shares in Q2 2026, an estimated $666K.
Climb Bio made up 0.82% of Sphera Funds Management's portfolio in Q2 2026, its #42 holding.
Sphera Funds Management first reported a position in Climb Bio in Q2 2024 and has held it in 9 quarters since.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.